APRINOIA Therapeutics Inc. (APRI)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	295.47M
Revenue (ttm)	9.13M -28.4%
Net Income	-21.74M
EPS	-0.81
Shares Out	26.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About APRI

APRINOIA Therapeutics is a clinical-stage biotechnology company committed to protecting patients’ brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. In harnessing the power of precision neuroscience, we are developing several different diagnostic and therapeutic platforms to detect and target both common and neurodegenerative disorders marked by abnormal protein aggregates of tau and alpha-synuclein (“α-Syn”) tha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: APRI
• Website: https://aprinoia.com/

Financial Performance

Data Source: SEC filings Last updated: Sep 4, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error